Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
or

Oyster Point Pharma Inc (OYST)

Oyster Point Pharma Inc (OYST)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
11.17 +0.02 (+0.18%) 12/30/22 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 11.17 unch (unch) -
Quote Overview for Fri, Dec 30th, 2022
Day Low
11.12
Day High
11.20
Open 11.16
Previous Close 11.15 11.15
Volume 2,088,200 2,088,200
Avg Vol 306,230 306,230
Stochastic %K 77.08% 77.08%
Weighted Alpha -44.20 -44.20
5-Day Change unch (unch) unch (unch)
52-Week Range 3.46 - 19.00 3.46 - 19.00
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 299,847
  • Shares Outstanding, K 26,844
  • Annual Sales, $ 24,540 K
  • Annual Income, $ -100,660 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 1.35
  • Price/Sales 12.20
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -6.65
  • Most Recent Earnings $-1.37 on 11/10/22
  • Next Earnings Date 02/23/23
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -1.19
  • Number of Estimates 2
  • High Estimate -1.16
  • Low Estimate -1.21
  • Prior Year -1.61
  • Growth Rate Est. (year over year) +26.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.04 +1.18%
on 12/23/22
Period Open: 11.18
11.25 -0.71%
on 12/01/22
-0.01 (-0.09%)
since 11/30/22
3-Month
5.17 +116.05%
on 10/03/22
Period Open: 5.62
11.83 -5.58%
on 11/07/22
+5.55 (+98.75%)
since 09/30/22
52-Week
3.46 +222.83%
on 06/22/22
Period Open: 18.96
19.00 -41.21%
on 12/31/21
-7.79 (-41.09%)
since 12/30/21

Most Recent Stories

More News
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IMGO, ELVT, LBC, OYST

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

IMGO : 36.01 (+0.03%)
ELVT : 1.8700 (+0.54%)
LBC : 9.15 (+0.55%)
OYST : 11.17 (+0.18%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates APEN, SAL, LBC, OYST

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

APEN : 10.00 (+0.81%)
SAL : 27.88 (+1.57%)
LBC : 9.15 (+0.55%)
OYST : 11.17 (+0.18%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AGFS, ATCO, LBC, OYST

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

AGFS : 3.00 (+0.33%)
ATCO : 15.48 (unch)
LBC : 9.15 (+0.55%)
OYST : 11.17 (+0.18%)
OYSTER POINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Oyster Point Pharma, Inc. - OYST

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Oyster Point Pharma, Inc. (NasdaqGS: OYST)...

OYST : 11.17 (+0.18%)
VTRS : 9.25 (+1.65%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OYST, LBC, ELVT, IMGO

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

OYST : 11.17 (+0.18%)
LBC : 9.15 (+0.55%)
ELVT : 1.8700 (+0.54%)
IMGO : 36.01 (+0.03%)
Better Dividend Stock: AbbVie or Viatris?

These pharmaceutical companies are profitable and offer above-average dividends.

PFE : 26.05 (+1.28%)
ABT : 127.64 (+0.73%)
OYST : 11.17 (+0.18%)
ABBV : 214.47 (+1.27%)
VTRS : 9.25 (+1.65%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BTRS, USER, AGFS, OYST

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

BTRS : 9.49 (-0.11%)
USER : 7.50 (-0.13%)
AGFS : 3.00 (+0.33%)
OYST : 11.17 (+0.18%)
SHAREHOLDER ALERT: Weiss Law Reminds AGTC, OYST, VLDR, and BTRS Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

AGTC : 0.3936 (+1.23%)
OYST : 11.17 (+0.18%)
VLDR : 1.2600 (+0.80%)
BTRS : 9.49 (-0.11%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ABMD, BNFT, OYST, VLDR

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

ABMD : 381.02 (+0.06%)
BNFT : 10.50 (+0.10%)
OYST : 11.17 (+0.18%)
VLDR : 1.2600 (+0.80%)
SHAREHOLDER ALERT: Weiss Law Reminds OYST, VLDR, ECOM, and LOTZ Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

OYST : 11.17 (+0.18%)
VLDR : 1.2600 (+0.80%)
ECOM : 23.09 (+0.04%)
LOTZ : 0.1480 (-1.99%)
OYSTER POINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Oyster Point Pharma, Inc. - OYST

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Oyster Point Pharma, Inc. (NasdaqGS: OYST)...

OYST : 11.17 (+0.18%)
VTRS : 9.25 (+1.65%)
SHAREHOLDER ALERT: Weiss Law Investigates Oyster Point Pharma, Inc.

/PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Oyster Point Pharma,...

OYST : 11.17 (+0.18%)
VTRS : 9.25 (+1.65%)
SHAREHOLDER ALERT: Halper Sadeh LLC Investigates OYST, OUST, and RBA

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

OYST : 11.17 (+0.18%)
OUST : 8.51 (+6.78%)
RBA : 97.98 (+2.26%)
Meta Platforms, Triumph Bancorp rise; IAA, Palantir fall

Stocks that traded heavily or had substantial price changes Monday: Meta Platforms, Triumph Bancorp rise; IAA, Palantir fall

AMG : 165.14 (+1.24%)
TBK : 58.74 (-1.71%)
OYST : 11.17 (+0.18%)
Why Viatris Stock Is Jumping Today

Investors are applauding a key step in Viatris' plans to return to growth.

VTRS : 9.25 (+1.65%)
OYST : 11.17 (+0.18%)
Oyster Point Pharma (NASDAQ: OYST) Enters Into Agreement to be Acquired by Viatris (NASDAQ: VTRS) For $11 Per Share Plus CVR Up to $2.00 Per Share

Oyster Point Pharma, Inc. (NASDAQ: OYST) is engaged as a commercial-stage biopharmaceutical company, which is focused on the research, development

OYST : 11.17 (+0.18%)
VTRS : 9.25 (+1.65%)
Shareholder Alert: Ademi LLP investigates whether Oyster Point Pharma, Inc. has obtained a Fair Price in its transaction with Viatris

/PRNewswire/ -- Ademi LLP is investigating Oyster Point Pharma (NASDAQ: OYST) for possible breaches of fiduciary duty and other violations of law in its...

OYST : 11.17 (+0.18%)
OYST Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Oyster Point Pharma, Inc. Is Fair to Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Oyster Point Pharma, Inc. (NASDAQ: OYST) to Viatris Inc. for $11.00 per share in cash plus a contingent value right for...

OYST : 11.17 (+0.18%)
Oyster Point Pharma, Inc. (OYST) Q2 2022 Earnings Call Transcript

OYST earnings call for the period ending June 30, 2022.

OYST : 11.17 (+0.18%)
Oyster Point Pharma To Report Second Quarter 2022 Financial Results On August 11, 2022

Conference Call and Webcast Scheduled for August 11, 2022, 4:30 p.m. ET PRINCETON, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc....

OYST : 11.17 (+0.18%)

Business Summary

Oyster Point Pharma Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of pharmaceutical therapies to treat ocular surface diseases. The company's lead product candidate, OC-01, is being developed as a nasal spray to treat the signs and...

See More

Key Turning Points

3rd Resistance Point 11.29
2nd Resistance Point 11.24
1st Resistance Point 11.21
Last Price 11.17
1st Support Level 11.13
2nd Support Level 11.08
3rd Support Level 11.05

See More

52-Week High 19.00
Fibonacci 61.8% 13.06
Fibonacci 50% 11.23
Last Price 11.17
Fibonacci 38.2% 9.40
52-Week Low 3.46

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Precision Trading with Bollinger Bands: Identifying Breakouts & Reversals

Info When You Need It Most.

Barchart Premier is one of the most powerful tools in the investment world. Come see why so many subscribers love it — and try it risk-free for 30 days.